Esophageal squamous cell carcinoma
Conditions
Interventions
Experimental group:Radiotherapy combined with tislelizumab
Sponsors
Binzhou Medical University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically proven II-IVa cervical and thoracic esophageal squamous cell carcinoma (UICC 2002 stage); 2. ECOG 0-1; life expectancy > 6 months; 3. Aged 18-80 years, no gender limit; at least able to take liquid diet; 4. No chemotherapy or radiotherapy was used before selection; 5. No history of immunotherapy; 6. No surgical treatment; 7. No serious allergic history; 8. Hemoglobin>=100 g/L, WBC >= 3.5x10^9/L, neutrophil >= 1.5x10^9, platelet >= 100 x 10^9/L; CR <= 1.5x upper limit of normal, TB <= 2.5x upper limit of normal, AST and ALT <= 2.5x upper limit of normal, AKP <= 2.5x upper limit of normal; 9. Barium meal angiography lesion length 10cm; 10. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. History of malignant tumors in other parts; 2. Duplicate carcinoma of the esophagus; 3. Pregnant or lactating patients; 4. Fertility but not using contraceptive measures; 5. Serious comorbidities: very high risk hypertension, severe pulmonary function damage, massive myocardial infarction, cardiac function >= grade II, mental history and severe diabetes; 6. During the active period of infectious diseases; 7. Participate in other clinical trials at present or within four weeks before enrollment; 8. Treatment with other anticancer drugs at the same time (including anticancer traditional Chinese medicine); 9. After esophageal stent placement; 10. Patients with perforation tendency; 11. Have a history of organ transplantation; 12. History of allergy to monoclonal antibodies or uncontrolled allergic asthma; 13. Suffering from active autoimmune disease or a history of autoimmune disease; 14. Patients with a history of primary immunodeficiency; 15. Suffering from interstitial lung disease or non-infectious pneumonia requiring hormone therapy, or active tuberculosis; 16. Any drug that has received T cell co-stimulation or checkpoint pathway; 17. Received attenuated or vaccine within 28 days prior to administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Countries
China
Contacts
Public ContactNing Fangling
Binzhou Medical University Hospital
Outcome results
None listed